Join the RoxyBond group to help and get support from people like you.
RoxyBond News
Fewer Opioids Being Prescribed for Low Back Pain in the Emergency Department
FRIDAY, July 18, 2025 – From 2016 to 2022, 5.3 percent of all U.S. emergency department visits were related to low back pain, with opioid administration and prescription decreasing during this same...
Opioids Tough To Prescribe For Legitimate Patients, Doctors Say
THURSDAY, April 24, 2025 — Patients who legitimately need opioid painkillers are finding it more difficult to get the meds they need, due to guardrails established in response to the U.S. opioid c...
OD Deaths Decline in U.S., Driven By Drop In Opioid Fatalities
FRIDAY, Feb. 21, 2025 – America’s opioid crisis is showing signs of subsiding, a new report from the U.S. Centers for Disease Control and Prevention (CDC) says. Drug overdose deaths (OD) decreased b...
Protega Pharmaceuticals Receives FDA Approval for RoxyBond (oxycodone hydrochloride) Immediate-Release 10 mg Tablet with Abuse-Deterrent Technology for Management of Pain
PRINCETON, N.J., Oct. 29, 2024 /PRNewswire/ – Protega Pharmaceuticals Inc., an innovative specialty pharmaceutical company focused on responsible pain management and the development of novel...
Painkiller Misuse Common Among People Battling Chronic Pain
THURSDAY, Aug. 8, 2024 – Nearly 1 in every 10 chronic pain patients treated with prescription opioids winds up addicted to the painkillers at some point, a new review finds. Further, nearly 1 in 3...
FDA Medwatch Alert: Drug Safety Communication: All Opioid Pain Medicines - FDA Updates Prescribing Information to Provide Additional Guidance for Safe Use
ISSUE: The FDA is requiring several updates to the prescribing information for both immediate-release (IR) and extended release/long acting (ER/LA) opioid pain medicines. This includes stating for a...
Inspirion Delivery Sciences Receives FDA Approval for RoxyBond (oxycodone hydrochloride) Immediate Release Tablets with Abuse-Deterrent Label Claims
BASKING RIDGE, N.J., April 26, 2017 /PRNewswire/ – Inspirion Delivery Sciences, LLC ("Inspirion") announced that the United States Food and Drug Administration (FDA) has approved RoxyBond™ (...